Mary Kay Fenton serves as Chief Financial Officer at Cullinan Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing differentiated small molecule and cellular therapies for cancer. With more than 25 years of finance and operations leadership in the life sciences sector, Fenton brings extensive expertise in capital markets, strategic financing, and scaling biotech organizations. She joined Cullinan in 2021, following senior roles at bluebird bio, where she was Senior Vice President of Finance, and Relypsa, Inc., where she served as CFO during its acquisition by Galencia for $1.3 billion. Fenton's career is marked by significant achievements, including leading over $2 billion in equity and debt financings across multiple companies. At bluebird bio, she oversaw financial strategy during a period of rapid clinical advancement and commercialization efforts for gene therapies. Earlier, at MAP Pharmaceuticals (acquired by Allergan), she played a key role in operational transformations and IPO preparations, demonstrating her ability to drive growth in high-stakes environments. At Cullinan Therapeutics, Fenton directs all financial functions, including investor relations, treasury, accounting, and capital allocation to support the company's oncology pipeline. Her leadership has been instrumental in securing substantial funding rounds, such as the company's $330 million IPO in 2021 and subsequent offerings, enabling progression of programs like the CLADE platform and zipalertinib toward late-stage development. Fenton's strategic insight continues to fuel Cullinan's mission to deliver transformative cancer treatments.